INFLAMASE FORTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for INFLAMASE FORTE (INFLAMASE FORTE).
Inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
| Metabolism | Hepatic metabolism primarily via CYP2C9; minor pathways involve CYP3A4 and conjugation. |
| Excretion | Approximately 95% renal: 90% as unchanged drug via glomerular filtration and tubular secretion, 5% as minor metabolites; 5% fecal via biliary elimination. |
| Half-life | Terminal half-life 36–42 hours in patients with normal renal function; prolonged to 18–26 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment. |
| Protein binding | 99.8% bound primarily to serum albumin, with minor binding to α1-acid glycoprotein. |
| Volume of Distribution | 0.12–0.14 L/kg, indicating limited extravascular distribution; primarily confined to central compartment. |
| Bioavailability | Oral: 85–95% (fasting); Administer with food to reduce GI irritation without significant change in extent. IM: 90–100%. IV: 100%. |
| Onset of Action | Oral: 1–2 hours; Intramuscular: 30–60 minutes; Intravenous: 5–15 minutes. |
| Duration of Action | Oral: 12–24 hours (single dose); IM/IV: 24–36 hours (single dose). Steady-state reached after 5–7 days of daily dosing. |
1-2 tablets (ibuprofen 400mg / pseudoephedrine 60mg) orally every 6 hours as needed; maximum 6 tablets per day.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | GFR >60 mL/min: no adjustment. GFR 30-60 mL/min: reduce dose by 50% or extend interval to 8-12 hours. GFR <30 mL/min: avoid use. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%; use with caution. Child-Pugh C: avoid use. |
| Pediatric use | Not recommended for children under 12 years of age. For children ≥12 years: 1 tablet (ibuprofen 400mg / pseudoephedrine 60mg) every 6 hours as needed; maximum 4 tablets per day. |
| Geriatric use | Start at lowest effective dose (e.g., 1 tablet every 8-12 hours). Monitor renal function and blood pressure; avoid prolonged use due to increased risk of gastrointestinal bleeding and cardiovascular events. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for INFLAMASE FORTE (INFLAMASE FORTE).
| Breastfeeding | Enters breast milk in low concentrations; M/P ratio not established. Use with caution due to potential for adverse effects in neonate. |
| Teratogenic Risk | First trimester: associated with increased risk of cardiac defects and gastroschisis. Second/third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, and fetal renal impairment. |
| Fetal Monitoring |
■ FDA Black Box Warning
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. Inflammase Forte is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
| Serious Effects |
Hypersensitivity to NSAIDs, history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs, perioperative pain in the setting of CABG surgery, advanced renal disease, and pregnancy (especially third trimester).
| Precautions | Cardiovascular risk, gastrointestinal bleeding, renal toxicity, hypertension, anaphylactoid reactions, serious skin reactions, hematologic toxicity, and fluid retention. |
Loading safety data…
| Monitor fetal ultrasound for ductus arteriosus patency, amniotic fluid volume, and fetal growth. Monitor maternal renal function and blood pressure. |
| Fertility Effects | May impair female fertility via inhibition of prostaglandin synthesis affecting ovulation and implantation; reversible upon discontinuation. |